Protara Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Protara Therapeutics, Inc. on June 9, 2020. The record date for the meeting was April 13, 2020, with 5,843,203 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting. The results were as follows:
- Proposal 1 (Election of Directors): Jesse Shefferman and Scott Braunstein, M.D. were elected as Class III directors.
- Jesse Shefferman: 3,788,044 votes For, 71,318 votes Withheld, 376,478 Broker Non-Votes.
- Scott Braunstein, M.D.: 3,777,735 votes For, 81,627 votes Withheld, 376,478 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- 4,201,471 votes For, 50 votes Against, 34,319 Abstentions.
- Proposal 3 (Say-on-Pay): Stockholders approved, on an advisory basis, the compensation of Named Executive Officers.
- 3,816,109 votes For, 10,763 votes Against, 32,490 Abstentions, 376,478 Broker Non-Votes.
- Proposal 4 (Frequency of Say-on-Pay): Stockholders indicated a preference for annual advisory votes on executive compensation.
- 3,826,411 votes For Every Year, 178 votes For Every Two Years, 183 votes For Every Three Years, 32,590 Abstentions, 376,478 Broker Non-Votes.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly details the outcomes of the stockholder vote.
Key Facts for Investor Verification
- Confirm the tenure of the newly elected directors (Jesse Shefferman and Scott Braunstein, M.D.) through the 2023 Annual Meeting.
- Verify the engagement of Marcum LLP as the independent auditor for the fiscal year ending December 31, 2020.
- Note the high level of support for executive compensation and the preference for annual say-on-pay votes.
- Review the definitive proxy statement referenced in the filing for detailed executive compensation disclosures.